imaging biomarker analysis

OTHER10 trials

Sponsors

University of Washington, Pfizer, University of Nebraska, Massachusetts General Hospital, Roswell Park Cancer Institute

Conditions

Bladder CancerBrain and Central Nervous System TumorsBreast CancerKidney CancerMalignant Pleural EffusionMetastatic CancerNo Evidence of DiseasePancreatic Cancer

Phase 1

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

WithdrawnNCT00635245

PfizerBreast Cancer

Updated: 2015-03-11

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

CompletedNCT01098344

Cancer Research UKPancreatic Cancer

Start: 2010-04-30End: 2014-10-31Updated: 2015-10-14

Phase 2

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

CompletedNCT00564733

University of WashingtonMalignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Start: 2007-10-31End: 2012-03-31Updated: 2017-02-10

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

TerminatedNCT00665457

University of NebraskaBreast Cancer

Start: 2004-04-15End: 2009-07-31Updated: 2023-09-13

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoBladder Cancer

Start: 2010-10-31Target: 45Updated: 2013-08-12

Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers

CompletedNCT02099136

National Cancer Institute (NCI)No Evidence of Disease

Start: 1999-09-30End: 2004-12-31Updated: 2016-12-29

Unknown Phase

MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma

TerminatedNCT00756106

Massachusetts General HospitalBrain and Central Nervous System Tumors

Start: 2008-07-31End: 2012-02-29Updated: 2020-05-13

Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

WithdrawnNCT00796874

Roswell Park Cancer InstituteProstate Cancer

Start: 2008-10-31End: 2013-07-31Updated: 2013-07-25

Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer

National Cancer Institute, FranceKidney Cancer, Metastatic Cancer

Start: 2007-12-31Target: 50Updated: 2013-08-12

Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32

Cancer and Leukemia Group BBreast Cancer

Start: 2012-08-31Target: 458Updated: 2013-07-10

Related Papers

Abstract PS3-01-30: Change in mammographic density (MD) with metformin use: Alliance A211201, A companion study to NCIC study MA.32

Clinical Cancer Research2026-02-17

Expert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation

Radiology Artificial Intelligence2023-11-227 citations

Radiomics Repeatability Pitfalls in a Scan-Rescan MRI Study of Glioblastoma.

2020-12-1634 citations

Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.

2017-09-127 citations

Molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib (S-GC) in muscle-invasive urothelial bladder carcinoma (MIBC): Insights for trials of new agents combined with chemotherapy in the field.

Journal of Clinical Oncology2017-05-20

MP34-13 NEOADJUVANT SORAFENIB, GEMCITABINE, AND CISPLATIN (SGC) FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIUBC): FINAL RESULTS AND TRANSLATIONAL FINDINGS OF AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.

The Journal of Urology2017-04-01

Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.

Journal of Clinical Oncology2017-02-201 citations

A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2014-05-209 citations

Updated analysis of circulating tumor cells (CTCs) in patients with urothelial cancer (UC) undergoing systemic treatment: Implications across the clinical stages.

Journal of Clinical Oncology2014-05-20

Quantification and molecular profiling of circulating tumor cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages.

Journal of Clinical Oncology2014-02-011 citations

Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).

Journal of Clinical Oncology2014-02-011 citations